Search

Displaying results 2341 - 2350 of 10000 in total
  1. Drug

    Auranofin

    go.drugbank.com/drugs/DB00995
    ApprovedInvestigational

    Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. … It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA.

    Synonyms: 2,3,4,6-Tetra-O-acetyl-1-thio-beta-D-glucopyranosato-S (triethylphosphine)gold
  2. Drug

    Streptococcus pneumoniae type 3 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10321
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 3 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 3 of *Streptococcus pneumoniae*.

    Mixtures: PREVENAR 13 SUSPENSION FOR INJECTION, PNEUMOVAX 23 Injektionslösung in einer Fertigspritze
  3. Drug

    Latanoprostene bunod

    go.drugbank.com/drugs/DB11660
    Approved

    The novelty of this agent subsequently lies in the proposed dual mechanism of action that stems from both its prostaglandin F2-alpha analog latanoprost acid metabolite and its ability to donate NO for … Conversely however, latanoprostene bunod integrates an NO-donating moiety in lieu of the isopropyl ester typically found in latanoprost.

  4. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    [L38814] While its approval was predated by two other members of the same drug family, namely [ubrogepant] and [rimegepant], these agents are indicated only for abortive migraine therapy - atogepant is … novel in that it is the first and only oral CGRP antagonist approved for preventative use in migraine.

  5. Drug

    Influenza B virus B/Washington/02/2019 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB15620
    ApprovedInvestigational

    Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3.

    Mixtures: Influvac Tetra, suspension for injection in pre-filled syringe, Vaxigrip Tetra, Suspension for Injection in Pre-filled Syringe
  6. Drug

    Dinutuximab

    go.drugbank.com/drugs/DB09077
    ApprovedInvestigational

    It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk … Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.

  7. Drug

    Orforglipron

    go.drugbank.com/drugs/DB18964
    ApprovedInvestigational

    [L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations. … Orforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist.

  8. Drug

    Raloxifene

    go.drugbank.com/drugs/DB00481
    ApprovedInvestigational

    women and reduction in risk for invasive breast cancer in postmenopausal women with osteoporosis or those who are at high risk for invasive breast cancer. … In addition, a clinical study consisting of postmenopausal women with documented coronary heart disease or at increased risk for coronary events showed an increased risk for fatal stroke with raloxifene

  9. Drug

    Epcoritamab

    go.drugbank.com/drugs/DB16672
    ApprovedInvestigational

    [L46516,L46556] In September 2023, epcoritamab was also approved in the EU for the same indication. … Although this regimen is effective in up to 60% of patients, patients with relapsed or refractory DLBCL have poor outcomes.

  10. Drug

    Nilutamide

    go.drugbank.com/drugs/DB00665
    ApprovedInvestigational

    Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). … Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer.

    Categories: Antiandrogens, non-steroidal